People · Operator
Named in public records as an officer, director or promoter · active 2010–2020 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Nuon Therapeutics Inc | — | Biotechnology | Series A | $29.7M | $361.5M | 2010 |
| Lengo Therapeutics, Inc. | — | Pharmaceuticals | Series B | $17.7M | $601.9M | 2020 |
Helen Jenkins at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Helen Jenkins on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Johnson | 1 | 35 |
| Robert More | 1 | 7 |
| Kim Kamdar | 1 | 6 |
| Bob More | 1 | 6 |
| Arlene Morris | 1 | 5 |
| Joshua Funder | 1 | 3 |
| Anna Chen | 1 | 3 |
| Daniel Estes, Ph.D. | 1 | 2 |
| Tito Serafini | 1 | 2 |
| Steve Bailey | 1 | 2 |
| Michael Kitt | 1 | 2 |
| Rodney Pearlman | 1 | 1 |
| Josh Funder | 1 | 1 |
| Lee Rauch | 1 | 1 |
| Paulette Dillon | 1 | 1 |
| Tracy Saxton, Ph.D. | 1 | 1 |
| Roger Ulrich, Ph.D. | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.